Long-Term Follow Up Study of Subjects Previously Administered HMI 102
Launched by HOMOLOGY MEDICINES, INC · Apr 13, 2020
Trial Information
Current as of July 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH Deficiency Previously Administered HMI 102. Subjects will have already received a single dose of HMI-102 administered intravenously
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject was previously administered HMI 102.
- • Subject is able to understand the purpose and risks of the study and is willing to provide informed consent.
- • Subject is able to comply with all study procedures and long-term follow-up.
- Exclusion Criteria:
- • Participation in the study is not in the subject's best interest, in the opinion of the Investigator.
About Homology Medicines, Inc
Homology Medicines, Inc. is a clinical-stage gene editing company focused on developing transformative genetic therapies for patients with rare diseases. Leveraging its proprietary gene editing platform, the company aims to provide innovative and durable treatment options by precisely correcting genetic mutations at the DNA level. With a robust pipeline of product candidates targeting conditions such as phenylketonuria (PKU) and other genetic disorders, Homology Medicines is committed to advancing the field of genetic medicine through rigorous clinical research and a patient-centric approach. The company is dedicated to improving patient outcomes and quality of life by addressing the underlying causes of genetic diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials